PM2.5 exposure is a significant risk factor for the occurrence and development of atherosclerosis. Polycyclic aromatic hydrocarbons (PAHs) play prominent roles in PM2.5-related toxicity. However, the nitrated derivatives of PAHs, nitrated polycyclic aromatic hydrocarbons (NPAHs), have strong oxidizing properties due to the nitro substituents. Thus, the in vivo and in vitro experiments exposure to benzo[a]pyrene (BaP) and 6-nitro benzo[a]pyrene (NBaP) were conducted to evaluate the effect of nitro substituent on the atherosclerosis due to (or attributable to) PAHs. The results showed that NBaP exposure induced the inhibition of human umbilical vein endothelial cells (HUVECs) viability and cell morphology damage via more severe oxidative stress than BaP exposure. Furthermore, exposure to PM2.5-bound NBaP caused dyslipidemia in the Apolipoprotein E-deficient (ApoE−/−) mice, including the increment of total cholesterol, triglycerides, low-density lipoprotein cholesterol, and malondialdehyde levels, and the decrement of high-density lipoprotein cholesterol levels, superoxide dismutase and glutathione peroxidase levels in serum and aorta. Furthermore, histology showed atherosclerotic plaque in the aorta of ApoE−/− mice. However, there were no significant differences of the physiological and pathological changes between BaP and control groups. Thus, NPAHs induced endothelial dysfunction and dyslipidemia via severe oxidative stress, and further accelerated the occurrence and development of atherosclerosis compared with the parent PAHs. Our findings provide the first evidence that nitro substituent caused much severer negative health impact of polycyclic aromatic compounds, which highlight the significance of NPAHs in health risk estimation of polycyclic aromatic compounds.